Trial · NCT00639457

Exercise and Pioglitazone for HIV-Metabolic Syndromes

NCT00639457, Not applicable, Completed, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); results first posted 2013-09-12

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Exercise and Pioglitazone for HIV-Metabolic Syndromes. Trials, record NCT00639457. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00639457

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Exercise and Pioglitazone for HIV-Metabolic Syndromes
NCT number: NCT00639457
Status: Completed
Phases: Not applicable
Enrollment: 44 participants, actual
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions: HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Interventions: Pioglitazone, Exercise training
First posted: 2008-03-20
Last updated: 2013-10-23
Results first posted: 2013-09-12
Limitations and caveats: No intervention and exercise training only control groups were not included. Intracellular mechanisms were not explored. Relatively small number of participants taking a variety of anti-HIV medication regimens.

Source ClinicalTrials.gov

Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Insulin-stimulated Glucose Disposal Rate	Baseline and week16	Insulin-mediated glucose disposal rate per kg of fat free mass per min
Secondary	Visceral Fat Volume	Baseline and week 16
Secondary	Abdominal Subcutaneous Fat Volume	Baseline and week 16
Secondary	Hepatic Lipid Content	Baseline and week 16
Secondary	Hepatic Glucose Production Rate	Baseline and week 16	ability of insulin to suppress hepatic glucose production = hepatic insulin sensitivity
Secondary	Serum Lipid and Lipoprotein Levels	Baseline and week 16
Secondary	Liver Enzyme Levels	Baseline and week 16
Secondary	Hemoglobin	Baseline and Week 16
Secondary	Hematocrit	Baseline and Week 16	Percentage of blood volume that is red cells
Secondary	Serum Adiponectin Levels	Baseline and week 16

1 to 10 of 15Source ClinicalTrials.gov

See all 15 registered outcomes

Outcomes15

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Insulin-stimulated Glucose Disposal Rate	Baseline and week16	µmol glucose/kg FFM/min	MEAN
SECONDARY	Visceral Fat Volume	Baseline and week 16	cm3	MEAN
SECONDARY	Abdominal Subcutaneous Fat Volume	Baseline and week 16	cm3	MEAN
SECONDARY	Hepatic Lipid Content	Baseline and week 16	percent of water	MEAN
SECONDARY	Hepatic Glucose Production Rate	Baseline and week 16	percent suppression	MEAN
SECONDARY	Serum Lipid and Lipoprotein Levels	Baseline and week 16	mM/L	MEAN
SECONDARY	Liver Enzyme Levels	Baseline and week 16	U/L	MEAN
SECONDARY	Hemoglobin	Baseline and Week 16	g/L	MEAN
SECONDARY	Hematocrit	Baseline and Week 16	% red cells	MEAN
SECONDARY	Serum Adiponectin Levels	Baseline and week 16	µg/mL	MEAN

1 to 10 of 15Source ClinicalTrials.gov

See all 15 outcomes

Results by group76

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Insulin-stimulated Glucose Disposal Rate	Pioglitazone	Baseline	30	Standard Error 4	µmol glucose/kg FFM/min
Insulin-stimulated Glucose Disposal Rate	Pioglitazone + Exercise Training	Baseline	34	Standard Error 4	µmol glucose/kg FFM/min
Insulin-stimulated Glucose Disposal Rate	Pioglitazone	Week 16	37	Standard Error 6	µmol glucose/kg FFM/min
Insulin-stimulated Glucose Disposal Rate	Pioglitazone + Exercise Training	Week 16	48	Standard Error 6	µmol glucose/kg FFM/min
Visceral Fat Volume	Pioglitazone	Baseline	1933	Standard Error 150	cm3
Visceral Fat Volume	Pioglitazone + Exercise Training	Baseline	1890	Standard Error 217	cm3
Visceral Fat Volume	Pioglitazone	Week 16	1970	Standard Error 164	cm3
Visceral Fat Volume	Pioglitazone + Exercise Training	Week 16	1746	Standard Error 177	cm3
Abdominal Subcutaneous Fat Volume	Pioglitazone	Baseline	2101	Standard Error 293	cm3
Abdominal Subcutaneous Fat Volume	Pioglitazone + Exercise Training	Baseline	1877	Standard Error 197	cm3

1 to 10 of 76Source ClinicalTrials.gov

See all 76 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pioglitazone	22
Overall Study	STARTED	Pioglitazone + Exercise Training	22
Overall Study	COMPLETED	Pioglitazone	20
Overall Study	COMPLETED	Pioglitazone + Exercise Training	19
Overall Study	NOT COMPLETED	Pioglitazone	2
Overall Study	NOT COMPLETED	Pioglitazone + Exercise Training	3

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pioglitazone
Total, all-cause mortality	Pioglitazone + Exercise Training
Total, other adverse events	Pioglitazone	0	20
Total, other adverse events	Pioglitazone + Exercise Training	0	19
Total, serious adverse events	Pioglitazone	0	20
Total, serious adverse events	Pioglitazone + Exercise Training	0	19

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
20959530	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Pioglitazone vs Pioglitazone + Exercise Training: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00639457

GET https://conductscience.org/api/trials/v1/NCT00639457/results?page=2

API reference For AI assistants